A higher level of knowledge about melanoma risk is associated with an increased likelihood of performing preventative behaviors, according to research presented at the 2023 ASCO Annual Meeting.
2023
Melanoma-Specific Survival Longer With Nivolumab Plus Relatlimab Combined Treatment
Nivolumab plus relatlimab showed a clear benefit in progression-free survival, overall survival and objective response rate.
Targeted Adjuvant Therapies Provide No Survival Benefit in Stage III Melanoma
Targeted adjuvant therapy does not improve outcomes in patients with stage III melanoma, according to a Swedish study published in the Journal of the National Cancer Institute.
A protective “base tan" is actually a harmful myth
With warmer temperatures and plenty of sunshine, it’s tempting to spend more time soaking up the rays.